Biosensors

The share price weakness of Biosensors could be due to continued stock sales by substantial shareholders, Fidelity and private equity firm Ever Union Capital, both of which recently sold down their stakes below 5%, which no longer requires them to declare further divestments. The company will release its 2QFY13 results on 7 Nov.